Phase 3 × Recruiting × 130-nm albumin-bound paclitaxel × Clear all Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Phase 3 Recruiting
416 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
MK-2870-010
Phase 3 Recruiting
1,200 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Phase 3 Recruiting
94 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3 Recruiting
524 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Phase 3 Recruiting
430 enrolled
TIGeR-PaC
Phase 3 Recruiting
190 enrolled
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Phase 3 Recruiting
602 enrolled
PTCA199-11
Phase 3 Recruiting
210 enrolled
TAB-2
Phase 3 Recruiting
220 enrolled
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Phase 3 Recruiting
360 enrolled
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Phase 3 Recruiting
778 enrolled